Abstract: The most frequently encountered RAMs are M204V/I: 48.8%, L180M: 33.3%, L80V: 28.8%, and V173L: 42.2%.
Result: M204V/I: 48.8%, plus L180M: 33.3% +- L80
Discussion: In our study, despite the frequent association of the primary resistance mutations M204V/I with the compensatory L180M, V173L, and L80V/I mutations, lamivudine-resistant HBV strains tend to be associated with lower viral loads compared to wild-type strains; further characterization of the viral strains, using Next-Generation Sequencing (NGS), might reveal the presence of other mutations that alter viral replication.
Reactivation of Occult Hepatitis B Virus Infection During Long-Term Entecavir Antiviral Therapy.
Result: This phenomenon is consistent with previous report, demonstrating that the rtL180M mutation in HBV polymerase is commonly accompanied by rtM204V or rtM204I mutations.
Discussion: This assay is relative not sensitive compared to our cloning and sequencing analysis, and cannot discriminate whether the two rtM204V and rtM204I mutations are separately or simultaneously exist in the same HBV genome.
Dried blood spot sampling for hepatitis B virus quantification, sequencing and mutation detection.
Abstract: An HIV-coinfected patient presented the rtM204V/I-rtL180M double resistance mutation in serum and DBS.
Result: One patient had the double resistance polymerase mutation rtM204V/I-rtL180M, in both serum and DBS.
Discussion: Regarding resistance mutations, the double rtM204V/I-rtL180M mutation in polymerase gene (to lamivudine, telbivudine and entecavir:partial) was observed in both serum and DBS samples from an HIV-treated patient.
Global prevalence and phylogeny of hepatitis B virus (HBV) drug and vaccine resistance mutations.
Abstract: RAM M204I/V had the highest prevalence, occurring in 3.8% (109/2838) of all HBV sequences in our data set, and a significantly higher rate in genotype C at 5.4% (60/1102, p = 0.0007).
Discussion: A previous meta-analysis estimated the prevalence of M204I/V as 4.9% among >12,000 treatment-naive individuals, and another review reported a prevalence of M204I/V of 5.9% among 8435 treatment-naive individuals.
Discussion: For example, RAMs in HBV reverse transcriptase, A181T/V, M204I and M204V, cause corresponding changes in the overlapping region of HBsAg (W172 stop, W196S/L/Stop and PMID: 33903819
2021
Molecular and clinical oncology
Abstract: Only the substitution M204I was detected in the HBV polymerase region.
Conclusion: ETVr-related substitution M204I was detected, but no other mutations were identified (Table II).
Introduction: In fact, resistance to ETV appears to occur through a two-hit mechanism with primary LVD resistance (LVDr) substitutions (M204V/I with/without rtL180M) followed by amino acid substitutions at the rtI169, rtT184, rtS202 or rtM250 sites.
Discussion: There were 8 mutations in the RT region, rtL80I,
rt269I Type of Hepatitis B Virus (HBV) Polymerase versus rt269L Is More Prone to Mutations within HBV Genome in Chronic Patients Infected with Genotype C2: Evidence from Analysis of Full HBV Genotype C2 Genome.
Discussion: Indeed, we found several rt269I signature mutation types related to lower HBV replication (I84T/M/L/V in PreS1, preC-W28Stop, V/L5M in X region, C-I97F/L in C region and rtM204I/V in RT region) or liver disease progression (three types in preC/C region (preC-W28Stop, C-
The Occurrence of rtA194T Mutant After Long-Term Lamivudine Monotherapy Remains Sensitive to Tenofovir Disoproxil Fumarate: A Case Report.
Discussion: Three mutations associated with LAM resistance have been mostly described: rtM204V/I in C domain, rtV173L and rtL180M in B domain.
Virologic analysis of tenofovir resistance in a patient with chronic hepatitis B experiencing viral breakthrough during combination treatment with tenofovir disoproxil fumarate and entecavir.
Abstract: A recent Korean report showed that two patients with viral breakthrough during treatment with TDF-containing regimens were found to carry five reverse transcriptase (rt) mutations ([rt]S106C[C], rtH126Y[Y], rtD134E[E], rtM204I/V, and rtL269I [I]), with the C, Y, E, and I mutations being associated with tenofovir resistance.
Rapid Turnover of Hepatitis B Virus Covalently Closed Circular DNA Indicated by Monitoring Emergence and Reversion of Signature-Mutation in Treated Chronic Hepatitis B Patients.
Abstract: APPROACH AND RESULTS: In this study, we retrospectively monitored the emergence and reversion of the rtM204I/V mutant, a signature lamivudine resistance (LAMR ) mutation serving as a biomarker of cccDNA turnover in liver biopsies and longitudinal serum samples from two clinical trials.
Method:
Method: Percentage Composition of rtM204I/V in HBV cccDNA, Viral DNA, and RNA.
Method: Percentages of rtM204I/V mutations were calculated using Sequencher software (Gene Codes, Ann Arbor, MI).
Figure: Percentage of LAMR rtM204I/V mutation in serum and liver biopsy samples of 5 EFFORT patients collected at week 104 and 2 ML18376 patients collected at baseline (A).
HBV mutation literature information.
PMID: 
2022
Medicina (Kaunas, Lithuania)
Browser Board
Co-occurred Entities
Filtrator
ViMRT